Key result
Combining existing antipsychotics with cardioprotective agents provides a beneficial strategy to minimize cardiotoxicity in patients with mental disorders.
Why the study?
Strategies to address antipsychotic cardiotoxic effects, such as substitution with newer antipsychotics or adjunct cardioprotective therapy, require clinical verification.
Does the use of newer antipsychotics or adjunct cardioprotective therapy prevent cardiotoxicity in patients with mental disorders?
Does the use of newer antipsychotics or adjunct cardioprotective therapy prevent cardiotoxicity in patients with mental disorders?
Substituting newer antipsychotics or adding cardioprotective agents are proposed strategies to mitigate antipsychotic-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May suggest newer antipsychotics or cardioprotective combinations to limit cardiotoxicity; leaves open prospective verification before practice change.
Use of newer antipsychotics for substitution of current antipsychotics might be one way awaiting to be clinically verified to address antipsychotic cardiotoxic effects. Alternatively, the combination of existing antipsychotics with cardioprotective agents is also beneficial for patients with mental disorders for avoiding cardiotoxicity to the maximum.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2022) studied this question. Combining existing antipsychotics with cardioprotective agents provides a beneficial strategy to minimize cardiotoxicity in patients with mental disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: